Scientific Program - Stroke

Print
Section Heads: Natan Bornstein, Israel & José Ferro, Portugal
Please see below the CONy Scientific Program. Please click on the appropriate section to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable / overview, please click here
 
For the full Scientific Program, please click here >
THURSDAY, MARCH 17, 2016
PLANERY STROKE LECTURES
Chair: Virgilio Bento, Portugal
11:00-11:30
Shifting the paradigm in brain protection and recovery
Dafin Muresanu, Romania
11:30-12:00 Role of exosomes/miRNA in mediating recovery after stroke and traumatic brain injury?
Michael Chopp, USA
12:00-12:30 Post-stroke cerebral reorganization
Jay P. Mohr, USA
FRIDAY, MARCH 18, 2016
08:30-10:30
PERSONALIZED MEDICINE FOR STROKE; ASYMPTOMATIC INTRACRANIAL ANEURYSMS
Chair: Boleslav Lichterman, Russia; Dimitar Maslarov, Bulgaria
08:30-09:30 Debate: Should asymptomatic intracranial aneurysm always be treated?
Capsule: Neuroimaging may discover incidentally intracranial aneurysms. This finding is often frightening for the patients and raises uncertainties to the treating physicians – to intervene or not to touch? This debate will address this question
08:30-08:40 Host: Jorge Campos, Portugal
08:40-08:55 To intervene: Pedro Castro, Portugal
08:55-09:10 No: Daniel Bereczki, Hungary
09:10-09:30 Discussion and rebuttals
09:30-10:30 Debate: Evidence-based medicine (EBM) vs. personalized medicine in stroke victims
Capsule: EBM based on randomized clinical trials (RCT's) is considered the "gold standard" in secondary stroke prevention therapy. However many question the generalizability of EBM approach and are convinced that "personalized" medicine is the more appropriate way to tailor the treatment to each individual patient. Which is the best approach?
09:30-09:40 Host: Jonathan Streifler, Israel
09:40-09:55 EBM: Antonio Vaz Carneiro, Portugal
09:55-10:10 Personalized: Lou Caplan, USA
10:10-10:30 Discussion and rebuttals
10:45-12:45 THE RELEVANCE OF GENETIC TESTING FOR STROKE; MANAGEMENT OF CAROTID DISSECTIONS
Chair: Elsa Azevedo, Portugal; Wei Wei Zhang, China
10:45-11:45 Proposition: Genetic testing for stroke will soon be clinically relevant
Capsule: Over the past few years, GWAS studies have identified several genetic markers for stroke. These include mainly those associated with atherosclerosis and their attributable risk is small. Will these genetic markers soon have immediate clinical applications?
10:45-10:55 Host: Natan Bornstein, Israel
10:55-11:10 Yes: Mike O'Sullivan, UK
11:10-11:25 No: Hugh Markus, UK
11:25-11:45 Discussion and rebuttals
11:45-12:45 Debate: Carotid dissection: Should anticoagulants be used?
Capsule: Carotid dissection is a common cause of acute ischemic stroke, especially in the young. The current guidelines and the common practice recommend the use of anticoagulants as the treatment of choice. Is it the best treatment?
11:45-11:55 Host: Dieter Heiss, Germany
11:55-12:10 Aspirin is all that is necessary: Hugh Markus, UK
12:10-12:25 Anticoagulants should be used: José Ferro, Portugal
12:25-12:45 Discussion and rebuttals
15:00-17:00
ABCD2 FOR TIA; ANTICOAGULANT TREATMENT AFTER STROKE
Chair: Manuel Correira, Portugal
15:00-16:00 Debate: Is the ABCD2 grading useful for clinical management of TIA patients?
Capsule: Stroke risk after TIA is high. The ABCD2 scale was established to identify high-risk TIA patients. Should the ABCD2 score influence and guide our management of TIA patients? Is it useful or maybe irrelevant?
15:00-15:10 Host: Dieter Heiss, Germany
15:10-15:25 Useful: Jonathan Streifler, Israel
15:25-15:40 Unhelpful: Natan Bornstein, Israel
15:40-16:00 Discussion and rebuttals
16:00-17:00 Debate: Starting anticoagulants in post-stroke atrial fibrillation (AF) patients: How soon?
Capsule: Anticoagulants are recommended in AF patients unless contraindicated. However, in all recent studies with NOAC's vs. warfarin in post-stroke patients, the treatment was started 7-10 days after stroke onset. Therefore it is still uncertain when anticoagulants should be started? Is it safe to start immediately after the onset of stroke?
16:00-16:10 Host: Victor Oliveira, Portugal
16:10-16:25 The sooner the better: Thorsten Steiner, Germany
16:25-16:40 No: Jay P. Mohr, USA
16:40-17:00 Discussion and rebuttals
17:15-19:00
THROMBOLYSIS AND THROMBECTOMY FOR ACUTE ISCHEMIC STROKE; TESTING FOR THROMBOPHILIA IN CRYPTOGENIC STROKE
Chair: Joanna Wojczal, Poland; Natan Bornstein, Israel
17:15-18:10 Debate: Endovascular therapy in acute stroke: Start with IV tPA or go directly to the catheter lab?
Capsule: Several RCT's demonstrated that thrombectomy is superior to IV tPA in selected patients. In most of the trials, about 80% of the patients received IV tPA prior to endovascular therapy. Thus it is still not clear whether this "bridging" concept is superior to the "directly to the catheter lab" policy. This debate will try to clarify this important issue
17:15-17:25 Host: Antonio Vaz Carneiro, Portugal
17:25-17:40 Start with IV tPA: Daniel Bereczki, Hungary
17:40-17:55 Directly to the catheter: João Sargento-Freitas, Portugal
17:55-18:10 Discussion and rebuttals
18:10-19:00 Debate: Testing for thrombophilia in cryptogenic stroke in the young: Is it useful?
Capsule: It is common practice to order an extensive battery of blood tests for thrombophilia in young patients with stroke of unknown etiology. Is this expensive battery of blood tests worth the cost?
18:10-18:20 Host: Ovidiu Bajenaru, Romania
18:20-18:35 Useful: Mike O'Sullivan, UK
18:35-18:50 No: José Ferro, Portugal
18:50-19:00 Discussion and rebuttals
SATURDAY, MARCH 19, 2016
08:30-10:20
ADVANCES IN BRAIN PROTECTION AND RECOVERY: FROM MOLECULES TO CONNECTOMES
Chairs: Jorge Lains, Portugal; Dafin Muresanu, Romania
08:30-09:25 Debate: Should pharmaceutical agents be used in early post-stroke neurorehabilitation?
Capsule: Pharmacological modulation stands as one of the most promising assets in supporting neurorecovery. There are two strategies to frame pharmacological intervention in brain protection and recovery. Monomodal agents (stimulating only plasticity) may be used at later time points after the onset of lesion because they may potentially induce adverse reactions during the acute period. Multimodal agents (usually biological drugs) are able to modulate endogenous processes supporting acute neuroprotection and long term recovery. Therefore, it is critically important to correctly use these pharmacological assets
08:30-08:40 Host: Heinrich Binder, Austria
08:40-08:55 Yes: Dafin Muresanu, Romania
08:55-09:10 No: Volker Hömberg, Germany
09:10-09:25 Discussion and rebuttals
09:25-10:20 Debate: Post-stroke neurorehabilitation: Compensation vs. Restoration
Capsule: Rehabilitation is a complex process through which disabled persons reach maximal physical, functional, cognitive and psychosocial recovery within the disabilities limits. Should therapeutically induced improvement function reflect acquisition of compensatory strategies or restoration of more normal movement patterns? Restoration involves the reappearance of motor patterns present prior to lesion whereas compensation involves the emergence of new motor strategies
09:25-09:35 Host: Dafin Muresanu, Romania
09:35-09:50 Compensation: Volker Hömberg, Germany
09:50-10:05 Restoration: John Krakauer, USA
10:05-10:20 Discussion and rebuttals
SUNDAY, MARCH 20, 2016
PLENARY LECTURES: BEYOND THE HORIZON SERIES
Chair: Amélia Nogueria Pinto, Portugal; Sadagat Huseynova, Azerbaijan
10:00-10:30 Beyond the horizon in stroke
Lou Caplan, USA